BCBS Louisiana coverage for Wegovy (Weight Loss)

Wegovy for weight loss (to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbid condition) is explicitly not covered for members whose contract EXCLUDES coverage of medications for obesity, weight loss, weight management, or weight maintenance. The document notes this exclusion applies to most member contracts.

Policy note: The policy explicitly states that coverage of medications for obesity, weight loss, weight management, or weight maintenance is considered an exclusion in most member contracts. The policy does not establish PA criteria for Wegovy for the weight_loss indication — it only establishes criteria for cv_risk_reduction and mash. The FDA-approved weight loss indication (adults/peds 12+ with obesity; adults overweight with comorbidity) is explicitly noted as not covered for contracts that exclude obesity medications.

Policy effective May 1, 2026 · verified June 2, 2026 · source: 00886%2020240812%20Wegovy%20semaglutideaccessible%20pdf.pdf

Wegovy for weight loss (to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbid condition) is explicitly not covered for members whose contract EXCLUDES coverage of medications for obesity, weight loss, weight management, or weight maintenance. The document notes this exclusion applies to most member contracts.

Policy note: The policy explicitly states that coverage of medications for obesity, weight loss, weight management, or weight maintenance is considered an exclusion in most member contracts. The policy does not establish PA criteria for Wegovy for the weight_loss indication — it only establishes criteria for cv_risk_reduction and mash. The FDA-approved weight loss indication (adults/peds 12+ with obesity; adults overweight with comorbidity) is explicitly noted as not covered for contracts that exclude obesity medications.

Policy effective May 1, 2026 · verified June 2, 2026 · source: 00886%2020240812%20Wegovy%20semaglutideaccessible%20pdf.pdf